Abstracts tagged "Janus kinase (JAK) and rheumatoid arthritis (RA)"

Abstract Number: 2547 • 2015 ACR/ARHP Annual Meeting
NIP-565, a Novel JAK1-Selective Inhibitor, for the Treatment of Rheumatoid Arthritis
Yuuki Hidaka¹, Takanori Nakamura², Tadashi Igarashi², Takeshi Nanya², Shuhei Hagiwara², Kazuya Takeuchi², Tomonori Yaguchi³, Yutaka Kawakami³ and Takeshi Naito², ¹Pharmaceutical Research Department, Nissan Chemical Industries,LTD., Saitama, Japan, ²Nissan Chemical Industries,LTD., Saitama, Japan, ³Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Non-selective Janus kinase (JAK) inhibitors have shown long-term efficacy in treating rheumatoid arthritis (RA). However, clinical efficacy is limited due to concerns of dose-limiting…
Abstract Number: 2487 • 2012 ACR/ARHP Annual Meeting
24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Mark C. Genovese¹, Edward Keystone², Peter Taylor³, Edit Drescher⁴, Pierre-Yves Berclaz⁵, Chin H. Lee⁵, Douglas E. Schlichting⁵, Scott D. Beattie⁵, Rosanne K. Fidelus-Gort⁶, Monica E. Luchi⁶ and William Macias⁵, ¹Division of Rheumatology, Stanford University, Palo Alto, CA, ²University of Toronto, Toronto, ON, Canada, ³NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁴Internal Medicine and Rheumatology, Veszprém Csolnoky Ferenc County Hospital, Department of Rheumatology and Physical Rehabilitation, Veszprém, Hungary, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶E361/309, Incyte Corporation, Wilmington, DE
Background/Purpose: Baricitinib (formerly LY3009104/INCB028050), a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT signaling pathway, has been evaluated in a 24 week blinded…
Abstract Number: 1331 • 2012 ACR/ARHP Annual Meeting
Once Daily High Dose Regimens of GLPG0634 in Healthy Volunteers Are Safe and Provide Continuous Inhibition of JAK1 but Not JAK2
Florence Namour¹, René Galien¹, Lien Gheyle², Frédéric Vanhoutte³, Béatrice Vayssière¹, Annegret Van der Aa³, Bart Smets³ and Gerben van 't Klooster³, ¹Galapagos SASU, Romainville, France, ²SGS Clinical Pharmacology Unit, Antwerp, Belgium, ³Galapagos NV, Mechelen, Belgium
Background/Purpose: GLPG0634 is an orally-available, selective inhibitor of Janus kinase 1 (JAK1) with an IC50 of 0.6 μM and a 30-fold selectivity over JAK2 in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].